Daniel H Palmer
Affiliation: University of Birmingham
- Cancer gene-therapy: clinical trialsDaniel H Palmer
CR UK Institute for Cancer Studies, University of Birmingham B15 2TT, UK
Trends Biotechnol 24:76-82. 2006..The challenge now is to translate these features into effective therapies that can supplement or supplant existing treatments...
- Systemic therapies for hepatocellular carcinomaDaniel H Palmer
Cancer Research UK Institute for Cancer Studies, Clinical Research Block, University of Birmingham, Birmingham B15 2TA, UK
Expert Opin Investig Drugs 13:1555-68. 2004..At present there are a number of interesting therapeutic agents with potential activity in HCC. The challenge now is the design of clinical trials to optimally evaluate these agents...
- Gene- and immunotherapy for hepatocellular carcinomaDaniel H Palmer
CR UK Institute for Cancer Studies, Clinical Research Block, University of Birmingham, Birmingham, B15 2TT, UK
Expert Opin Biol Ther 5:507-23. 2005..The challenge remains to design clinical trials to optimally evaluate these agents and allow feedback to the laboratory for their ongoing development...
- CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirusTaha Elmetwali
Cancer Research UK Institute for Cancer Studies, School of Cancer Sciences, University of Birmingham, UK
Mol Cancer 9:52. 2010..The most profound induction of cell death in carcinoma cells is induced by membrane-bound rather than recombinant soluble CD40L, but like other TNF family ligands, it is cleaved from the membrane by matrix metalloproteinases...
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinomaDaniel H Palmer
Cancer Research UK Clinical Trials Unit, CR UK Institute for Cancer Studies, Clinical Research Block
Hepatology 49:124-32. 2009..Immune responses were assessed using an ELIspot assay of interferon-gamma (IFN-gamma) release. In several cases there was induction of T cell responses to the vaccine and/or AFP following vaccination...
- Endocrine therapy and other targeted therapies for metastatic breast cancerSyed A Hussain
Cancer Research UK, Institute for Cancer Studies and The Cancer Centre, Queen Elizabeth Hospital, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Expert Rev Anticancer Ther 4:1179-95. 2004..These include strategies to overcome endocrine resistance and methods to target deregulated endocrine and growth factor signaling pathways using gene and immunotherapy approaches...
- Role of chemotherapy in breast cancerSyed A Hussain
Institute for Cancer Studies, University Hospital Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Expert Rev Anticancer Ther 5:1095-110. 2005..This review discusses the evidence for various chemotherapy regimens in the adjuvant and metastatic settings, and examines the current evidence for the timing of radiotherapy in the adjuvant setting...
- Molecularly targeted therapeutics for breast cancerSyed A Hussain
Cancer Research UK, Institute for Cancer Studies, University Hospital Birmingham, Birmingham, England
BioDrugs 21:215-24. 2007....
- Clinical experience with adenovirus in cancer therapyDaniel H Palmer
CR UK Institute for Cancer Studies, The Medical School, University of Birmingham, Edgbaston, UK
Curr Opin Mol Ther 4:423-34. 2002..It is anticipated that adenovirus-mediated gene therapy will be integrated with existing treatment modalities, including surgery, chemotherapy and radiotherapy, to facilitate improvement in cancer treatments in the future...
- Biology of testicular germ cell tumorsSyed A Hussain
Cancer Research UK Institute for Cancer Studies, University of Birmingham, University Hospital Birmingham NHS Foundation Trust, Edgbaston, Birmingham, UK
Expert Rev Anticancer Ther 8:1659-73. 2008..Current understanding of the role of genetic and epigenetic factors in the etiology of germ cell tumors and the biochemical mechanisms underlying chemotherapy sensitivity and resistance is discussed in detail in this review...
- Gemcitabine chemotherapy until symptomatic disease progression in advanced pancreatic cancer: A retrospective analysisYuk Ting Ma
The Cancer Centre, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom Cancer Research UK Institute for Cancer Studies, Birmingham, United Kingdom School of Cancer Sciences, Birmingham, United Kingdom CRUK Institute for Cancer Studies, Birmingham, United Kingdom
J Clin Oncol 30:372. 2012....
- A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatinDaniel H Palmer
Cancer Research UK Institute for Cancer Studies and Clinical Trials Unit, University of Birmingham, Vincent Drive, Birmingham, B15 2TT, United Kingdom
Ann Surg Oncol 14:2088-96. 2007..This randomized phase 2 study compares gemcitabine-based chemotherapy regimens to identify the most promising regimen for future study...
- CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signalsTaha Elmetwali
Cancer Research United Kingdom Institute for Cancer Studies, School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
J Immunol 184:1111-20. 2010..These data provide mechanistic insights into the consequences of CD40 activation in carcinoma cells and how these might be exploited in the clinical development of CD40-targeted anticancer therapies...
- Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancerDaniel H Palmer
Cancer Research UK Institute for Cancer Studies, Department of Pathology and Liver Research Laboratories, University of Birmingham, UK
J Clin Oncol 22:1546-52. 2004..In this study, we report the first clinical trial investigating the feasibility, safety, and transgene expression of a replication-defective adenovirus encoding nitroreductase (CTL102) in patients with liver tumors...
- Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladderSyed A Hussain
Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Oncol Rep 11:1005-10. 2004..94). There was a trend towards longer survival for tumour expressing CA IX strongly. This is likely to be a reflection of the significantly higher rate of strong CA IX expression in non-invasive cancers influencing these survival data...
- Gene therapy for colorectal cancerDaniel H Palmer
CRUK Institute for Cancer Studies, The Medical School, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TF, UK
Br Med Bull 64:201-25. 2002..It is likely that gene therapy will be integrated into pre-existing therapies including surgery, chemotherapy and radiotherapy to establish its niche in tomorrow's medicine...
- Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapyKai S Lipinski
ML Research, Keele University Science Park, Keele, Staffordshire ST5 5SP, UK
Mol Ther 10:150-61. 2004..CTP4 should be the promoter of choice for Ad-based gene therapies of tumors deregulated for beta-catenin. We provide preliminary evidence that these may include prostate and ovarian as well as colorectal cancer...
- Pre-operative locoregional therapy and liver transplantation for hepatocellular carcinoma: time for a randomized controlled trialDaniel H Palmer
Am J Transplant 5:641-2. 2005
- Trial of adjuvant gemcitabine for pancreatic cancer: the jury is still outDaniel H Palmer
Pancreatology 7:548; author reply 549. 2007